| Literature DB >> 32049051 |
Yi Zhou1, Mingjian Fei1, Gu Zhang1, Wei-Ching Liang1, WeiYu Lin1, Yan Wu1, Robert Piskol1, John Ridgway1, Erin McNamara1, Haochu Huang1, Juan Zhang1, Jaehak Oh1, Jaina M Patel2, Diana Jakubiak1, Jeff Lau1, Beth Blackwood1, Daniel D Bravo1, Yongchang Shi1, Jianyong Wang1, Hong-Ming Hu2, Wyne P Lee1, Rajiv Jesudason1, Dewakar Sangaraju1, Zora Modrusan1, Keith R Anderson1, Søren Warming1, Merone Roose-Girma1, Minhong Yan3.
Abstract
Clearance of apoptotic cells by macrophages prevents excessive inflammation and supports immune tolerance. Here, we examined the effect of blocking apoptotic cell clearance on anti-tumor immune response. We generated an antibody that selectively inhibited efferocytosis by phagocytic receptor MerTK. Blockade of MerTK resulted in accumulation of apoptotic cells within tumors and triggered a type I interferon response. Treatment of tumor-bearing mice with anti-MerTK antibody stimulated T cell activation and synergized with anti-PD-1 or anti-PD-L1 therapy. The anti-tumor effect induced by anti-MerTK treatment was lost in Stinggt/gt mice, but not in Cgas-/- mice. Abolishing cGAMP production in Cgas-/- tumor cells, depletion of extracellular ATP, or inactivation of the ATP-gated P2X7R channel also compromised the effects of MerTK blockade. Mechanistically, extracellular ATP acted via P2X7R to enhance the transport of extracellular cGAMP into macrophages and subsequent STING activation. Thus, MerTK blockade increases tumor immunogenicity and potentiates anti-tumor immunity, which has implications for cancer immunotherapy.Entities:
Keywords: MerTK; P2X7R; STING; cGAS; cancer immunotherapy; efferocytosis; innate immunity; tumor-associated macrophage; type I IFN
Year: 2020 PMID: 32049051 DOI: 10.1016/j.immuni.2020.01.014
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745